GlassScriptPhysician profile
Teresa Thomas
NPI 1902175854
$4,382.55
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $189 · 2021: $62.15 · 2022: $1,060 · 2023: $1,691 · 2024: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,800.42 | 2021-2024 | Epclusa, Biktarvy, Sunlenca |
| Viiv Healthcare Company | $1,462.77 | 2021-2024 | Dovato, Apretude, Cabenuva |
| Merck Sharp & Dohme LLC | $372.53 | 2020-2023 | Pifeltro |
| Abbvie INC. | $251.94 | 2020-2024 | Mavyret |
| Novo Nordisk INC | $125.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.39 | 2019 | |
| Lilly USA, LLC | $53.34 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $47.71 | 2019-2020 | |
| Amarin Pharma, INC. | $43.25 | 2019 | |
| Amgen INC. | $29.20 | 2019-2020 | |
| Glaxosmithkline, LLC. | $25.97 | 2024 | Arexvy, Shingrix |
| Dynavax Technologies Corporation | $24.75 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.24 | 2019 | |
| Vifor Pharma, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.